Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-16T21:14:24.143Z Has data issue: false hasContentIssue false
  • English
  • Français

Thrombolytic Treatment of Acute Cerebral Infarction

Published online by Cambridge University Press:  07 November 2014

Kathleen M. Burger  and
Deborah R. Horowitz
Get access Rights & Permissions [Opens in a new window]

Abstract

Stroke is a common cause of death and disability throughout the world. Acute neurologic deficits due to ischemic injury deserve rapid recognition and diagnosis in order to provide effective therapy. Intravenous tissue plasminogen activator (t-PA) provided to carefully selected patients that can be treated within 3 hours of stroke onset results in improved outcome in these patients. Intra-arterial administration of t-PA within a 6-hour window is performed at several academic centers in patients with middle cerebral and other intracranial artery occlusions based on results of one randomized clinical trial and numerous case reports. Although acute therapy of ischemic stroke has received much attention since the approval of intravenous t-PA, only a small percentage of individuals suffering a stroke actually receive t-PA. This article will review the optimal management of the acute stroke patient and discuss thrombolytic clinical trials that have been completed as well as those that are in progress.

Type
Review Articles
Information
CNS Spectrums , Volume 10 , Issue 7 , July 2005 , pp. 539 - 549
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Brown, RD, Whisnant, JP, Sicks, JD, O'Fallon, WM, Wiebers, DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373–380.Google Scholar
2.Broderick, J, Brott, T, Kothari, R, et al.The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415–421.Google Scholar
3.Morris, D, Schroeder, E. Stroke epidemiology 2-9. Available at: http://www.uic.edu/com/ferne/pdf/strokeepi0501.pdf. Accessed 06 1, 2005.Google Scholar
4.Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic sttoke: a randomized controlled trial. The Publications Committee fot the Trial of ORG 10172 in Acute Sttoke Treatment (TOAST) Investigators. JAMA. 1998;279:1265–1272.Google Scholar
5.The International Stroke Trial (1ST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569–1581.Google Scholar
6.Bath, PM, Iddenden, R, Bath, FJ. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke. 2000;31:1770–1778.Google Scholar
7.Adams, HP Jr, Adams, RJ, Brott, T, et al.Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:1056–1083.CrossRefGoogle ScholarPubMed
8.Mohr, JP, Thompson, JL, Lazar, RM, et al.A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–1451.CrossRefGoogle ScholarPubMed
9.CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group, Lancet. 1997;349:1641–1649.Google Scholar
10.Silver, B, Weber, J, Fisher, M, et al.Medical therapy for acute ischemic stroke. Clin Neuropharmacol. 1996:101–128.CrossRefGoogle Scholar
11.Grotta, J. Combination Therapy Stroke Trial: rt-PA +/− Lebeluzole [abstract]. Stroke. 2000;31:278.Google Scholar
12.Lyden, P. Safety and efficacy of combined clomethiazole and t-PA for acute stroke-class T: a piloty study. Neurology. 2000;54(suppl 3):A88.Google Scholar
13.Sacco, R, Phillips, S, Haley, E, et al.Efficacy and safety of GV150526 in acute stroke: results of the GAIN Americas Trial (glycine antagonist in neuroprotection), Neurology. 2000;54(suppl 3):A87.Google Scholar
14.Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581–1587.Google Scholar
15.Donnan, GA, Davis, SM, Chambers, BR, et al.Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA. 1996;276:961–966.Google Scholar
16.Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial–Italy (MAST-I) Group. Lancet. 1995;346:1509–1514.CrossRefGoogle Scholar
17.Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial–Europe Study Group. N Engl J Med. 1996;335:145–1050.Google Scholar
18.Phan, TG, Wijdicks, EF. Intra-arterial thrombolysis for vertebrobasilar circulation ischemia. Crit Care Clin. 1999;15:719–742.Google Scholar
19. Brain Attack Coalition Web site. Availabe at: www.stroke-site.org. NINDS stroke division. Accessed on 06 1, 2005.Google Scholar
20.Lyden, P, Brott, T, Tilley, B, et al.Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25:2220–2226.Google Scholar
21.Brott, T, Lu, M, Kothari, R, et al.Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998;29:1504–1509.CrossRefGoogle ScholarPubMed
22.von Kummer, R, Nolte, PN, Schnittger, H, Thron, A, Ringelstein, EB. Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of stroke. Neuroradiology. 1996;38:31–33.Google Scholar
23.Warach, S, Chien, D, Li, W, Ronthal, M, Edelman, RR. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology. 1992;42:1717–1723.Google Scholar
24.Albers, GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 1999;30:2230–2237.CrossRefGoogle ScholarPubMed
25.Lyden, P. Thrombolytic Therapy For Stroke. Totowa, NJ: Humana Press Inc.; 2001.CrossRefGoogle ScholarPubMed
26.Shapiro, J, Bessette, M, Levine, SR, Baumlin, K. HandiStroke: a handheld tool for the emergent evaluation of acute stroke patients. Acad Emerg Med. 2003;10:1325–1328.Google Scholar
27. Foundation for Education and Research in Neurological Emergencies Web site. Available at: http://www.ferne.org. Accessed on 06 1, 2005.Google Scholar
28.Cadilhac, DA, Ibrahim, J, Pearce, DC, et al.Multicenter comparison of processes of care between Stroke Units and conventional care wards in Australia. Stroke. 2004;35:1035–1040.CrossRefGoogle ScholarPubMed
29.Product information section for Genentech, Inc. In: Physicians Desk Reference. 58th ed. Medical Economics Company Inc. 2004:1297–1301.Google Scholar
30.Marler, J, Tilley, B, Lu, M, et al., Earlier treatment associated with better outcome in the NINDS tpa stroke study [abstract]. Stroke. 1999;30:244.Google Scholar
31.Kidwell, CS, Saver, JL, Mattiello, J, et al.Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47:462–469.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
32.Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28:2109–2118.Google Scholar
33.Patel, SC, Levine, SR, Tilley, BC, et al.Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:2830–2838.CrossRefGoogle ScholarPubMed
34.Tejima, E, Katayama, Y, Suzuki, Y, Kano, T, Lo, EH. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke. 2001;32:1336–1340.Google Scholar
35.Demchuk, AM, Tanne, D, Hill, MD, et al.Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474–80.CrossRefGoogle ScholarPubMed
36.Alvarez-Sabin, J, Molina, CA, Montaner, J, et al.Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke. 2003;34:1235–1241.Google Scholar
37.Linfante, I, Llinas, RH, Selim, M, et al.Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke. 2002;33:2066–2071.CrossRefGoogle ScholarPubMed
38.Tanne, D, Kasner, SE, Demchuk, AM, et al.Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105:1679–1685.Google Scholar
39.Katzan, IL, Furlan, AJ, Lloyd, LE, et al.Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283:1151–1158.CrossRefGoogle ScholarPubMed
40.Albers, GW, Bates, VE, Clark, WM, Bell, R, Verro, P, Hamilton, SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145–1150.CrossRefGoogle ScholarPubMed
41.Hill, M, Woolfendeu, A, Teal, P, et al.Intravenous alteplase for stroke: the Canadian experience. The Stroke Interventionalist. 2000;2:3–8.Google Scholar
42.Kwiatkowski, TG, Libman, RB, Frankel, M, et al.Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:1781–1787.Google Scholar
43.Graham, GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34:2847–2850.Google Scholar
44.Fagan, SC, Morgenstern, LB, Petitta, A, et al.Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883–890.CrossRefGoogle ScholarPubMed
45.Hacke, W, Kaste, M, Fieschi, C, et al.Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–2105.Google Scholar
46.Hacke, W, Kaste, M, Fieschi, C, et al.Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245–1251.Google Scholar
47.Clark, WM, Wissman, S, Albers, GW, Jhamandas, JH, Madden, KP, Hamilton, S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019–2026.Google Scholar
48.Hacke, W, Donnan, G, Fieschi, C, et al.Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–774.Google ScholarPubMed
49.Nedeltchev, K, Arnold, M, Brekenfeld, C, et al.Pre- and in-hospital delays from stroke onset to intra-arterial thrombolysis. Stroke. 2003;34:1230–1234.Google Scholar
50.Qureshi, Al, Siddiqui, AM, Kim, SH, et al.Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol. 2004;25:322–328.Google Scholar
51.Alexandrov, AV, Grotta, JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59;862–867.Google Scholar
52.Furlan, A, Higashida, R, Wechsler, L, et al.Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003–2011.Google Scholar
53.Wechsler, LR, Jungreis, CA. Jungreis, Intra-arterial thrombolysis for carotid circulation ischemia. Crit Care Clin. 1999;15:701–718.Google Scholar
54.Zeumer, H, Freitag, HJ, Zanella, F, Thie, A, Arning, C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology. 1993;35:159–162.Google Scholar
55.Kidwell, CS, Saver, JL, Carneado, J, et al.Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke. 2002;33:717–724.Google Scholar
56.Bourekas, EC, Slivka, AP, Shah, R, Sunshine, J, Suarez, JI. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Neurosurgery. 2004;54:39–44; discussion 44-46.Google Scholar
57.Brandt, T, von Kummer, R, Muller-Kuppers, M, Hacke, W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke. 1996;27:875–881.Google Scholar
58.Ezaki, Y, Tsutsumi, K, Onizuka, M, et al.Retrospective analysis of neurological outcome after intra-arterial thrombolysis in basilar artery occlusion. Surg Neurol. 2003;60:423–429; discussion 429-430.Google Scholar
59.Lewandowski, CA, Frankel, M, Tomsick, TA, et al.Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598–6O5.CrossRefGoogle ScholarPubMed
60.IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35:904–911.Google Scholar
61.Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators. Stroke. 1994;25:1755–1759.CrossRefGoogle Scholar
62.Sherman, DG, Atkinson, RP, Chippendale, T, et al.Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA. 2000;283:2395–2403.CrossRefGoogle ScholarPubMed
63. Dose escalation study of desmoteplase in acute ischemic stroke page. Stroke Internet Directory/Internet Stroke Center Web site. Available at: http://www.strokecenter.org/trials/TrialDetail.asp?ref=470. Accessed 06 1, 2005.Google Scholar
64.Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. The Abciximab in Ischemic Stroke Investigators. Stroke. 2000;31:601–609.CrossRefGoogle Scholar
65.Abestt Investigators. Effects of abciximab for acute ischemic stroke: final results of Abciximab in Emergent Stroke Treatment Trial (Abestt) Stroke. 2003;34:252.Google Scholar
66.Hacke, W, Albers, G, Al-Rawi, Y, et al.The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2004;36:66–73.CrossRefGoogle Scholar
67.Qureshi, Al, Pande, RU, Kim, SH, Hanel, RA, Kirmani, JF, Yahia, AM. Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Irvestig Drugs. 2002;3:1729–1732.Google Scholar
68.Nakano, S, Iseda, T, Yoneyama, T, Kawano, H, Wakisaka, S. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis. Stroke. 2002;33:2872–2876.Google Scholar
69.Schumacher, HC, Meyers, PM, Yavagal, DR, et al.Endovascular mechanical thrombectomy of an occluded superior division branch of the left MCA for acute cardioembolic stroke. Cardiovasc lntervent Radiol. 2003;26:305–308.CrossRefGoogle ScholarPubMed
70.Daffertshofer, M, Fatar, M. Therapeutic ultrasound in ischemic stroke treatment: experimental evidence. Eur J Ultrasound. 2002;16:121–130.CrossRefGoogle ScholarPubMed
71.Alexandrov, AV, Molina, CA, Grotta, JC, et al.Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:2170–2178.Google Scholar
72.Berlis, A, Lutsep, H, Barnwell, S, et al.Mechanical thrombolysis in acute ischemic stroke with endovascular photoacoustic recanalization. Stroke. 2004;35:1112–1116.Google Scholar